NASDAQ: KALVKalvista Pharmaceuticals Inc Stock
$16.90-0.01 (-0.06%)
Updated Dec 15, 2025
KALV Price
$16.90
Fair Value Price
$1.86
Market Cap
$854.23M
52 Week Low
$7.30
52 Week High
$17.30
P/E
N/A
P/B
50.25x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
19
Operating Cash Flow
N/A
Beta
0.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KALV Overview
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KALV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KALV
Ranked#230 of 487
Ranked#230 of 487
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.14 | A | |
| $310.67 | A | |
| $7.59 | A |
Be the first to know about important KALV news, forecast changes, insider trades & much more!
KALV News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KALV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KALV ($16.90) is overvalued by 808.77% relative to our estimate of its Fair Value price of $1.86 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KALV ($16.90) is not significantly undervalued (808.77%) relative to our estimate of its Fair Value price of $1.86 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KALV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more KALV due diligence checks available for Premium users.
Valuation
KALV fair value
Fair Value of KALV stock based on Discounted Cash Flow (DCF)
Price
$16.90
Fair Value
$1.86
Overvalued by
808.77%
KALV ($16.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KALV ($16.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KALV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
148.94x
Market
45.07x
KALV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
50.25x
Industry
5.3x
KALV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KALV's financial health
Profit margin
Revenue
$13.7M
Net Income
-$49.5M
Profit Margin
-361.4%
Assets to liabilities
Assets
$339.9M
Liabilities
$322.9M
Debt to equity
19
KALV's short-term assets ($325.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KALV's short-term assets ($325.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KALV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KALV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
KALV vs Biotech Stocks
Kalvista Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.